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Abstract
Background YM758 monophosphate is a novel If chan-
nel inhibitor that has an inhibitory action for If current and
shows a strong and specific activity, selectively lowering
the heart rate and decreasing oxygen consumption by heart
muscle.
Objectives The objectives of the current study were to
investigate the in vivo metabolic profiles of YM758 in
mice, rats, rabbits, dogs, and monkeys and to elucidate the
structures of YM758 metabolites.
Methods Biological samples were analyzed by liquid
chromatography hyphenated with a radiometric detection
system and liquid chromatography coupled with a mass
spectrometer to clarify their metabolic patterns. To eluci-
date their structures, metabolites were isolated and ana-
lyzed by mass spectrometry and nuclear magnetic
resonance spectroscopy.
Results Our results from in vivo metabolic profiling in
humans and animals indicated there is no significant spe-
cies difference in the metabolism of YM758, and the
metabolic pathways of YM758 are considered to be oxi-
dation, hydration, and demethylation followed by sulfate or
glucuronide conjugation.
Key Points
We conducted quantitative metabolic profiling in rats
using 14C-YM758, and metabolism was considered
to be diverse.
The results of metabolic profiling in mice, rats,
rabbits, dogs, and monkeys suggest there are no
human-specific circulating metabolites.
The YM758 metabolites were elucidated by mass
spectrometry and nuclear magnetic resonance, and
the main metabolic pathways of YM758 in rats are
thought to be (1) hydroxylation and (2) oxidation
followed by hydration, (3) amide hydrolysis, and (4)





yl}-4-fluorobenzamide monophosphate (Fig. 1), has an
inhibitory action for the If current and shows a strong and
specific activity, selectively lowering the heart rate and
decreasing the oxygen consumption of heart muscle. As
such, it is useful as a preventive and/or treating agent for
diseases of the circulatory system, such as ischemic heart
diseases (e.g., angina pectoris and myocardial infarction),
congestive heart failure, and arrhythmia, etc. [1]. In clinical
trials, it has been reported that the If channel inhibitors
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zatebradine and ivabradine reduce the heart rate without
concomitant negative inotropic or hypotensive effects [2–
5]. The pharmacokinetic profiles of YM758 in humans and
test animals have been investigated elsewhere [6–8];
however, the inter-species differences in its metabolic
profile and the structures of the metabolites have not yet
been described. It is important to investigate the metabolite
profile in experimental animals to understand the differ-
ence in pharmacologic and toxicological effects of the
drug. The objectives of the current study were to investi-
gate the in vivo metabolic profiles of YM758 in mice, rats,
rabbits, dogs, and monkeys and elucidate the structures of
the metabolites of YM758.
2 Materials and Methods
2.1 Chemicals
YM758 monophosphate, YM-385459 (R3), YM-252124
(R4), YM-385461 (R8), YM-234903 (R9), and
AS2036329-00 (R16) (Fig. 1) were synthesized at Astellas
Pharma Inc. (Ibaraki, Japan). 14C-YM758 monophosphate
(98 % radiochemical purity, 3.14 MBq/mg), was synthe-
sized at Sekisui Medical (Ibaraki, Japan). All commercially
available regents used in this study were of the highest
quality and analytical grade. We used acetonitrile (Kanto
Chemical, Tokyo, Japan) and ammonium acetate (Na-
calaiTesque, Kyoto, Japan) to prepare the high-perfor-
mance liquid chromatography (HPLC) mobile phase, and
pico-fluor 40 (PerkinElmer; Wellesley, MA, USA) for
scintillation counting.
2.2 Equipment
We used an LC-10A HPLC system (Shimadzu, Kyoto,
Japan) with a fraction collector SF-2120 (Advantec, Tokyo,
Japan) to isolate metabolites and Q-TOF Ultima (Waters,
Milford, MA, USA) and TSQ7000 (Thermo Fisher Scien-
tific, Waltham, MA, USA) for mass spectrometry (MS)
analysis. JNM-ALPHA500 (JEOL, Tokyo, Japan) and
INOVA600 (Varian, Palo Alto, CA, USA) were used for
nuclear magnetic resonance (NMR) spectroscopy analysis.
An LC-VP HPLC system (Shimadzu) with a radiometric
detector FLO-ONE/A525AX (PerkinElmer) was used for
liquid chromatography (LC), coupled with a radiometric
detection system (LC-RAD), to investigate in vivo meta-
bolic profiles in rat urine and bile. A fraction collector DC-
1500 (EYELA, Tokyo Japan) and a liquid scintillation
counter 2700TR (PerkinElmer) were also used for meta-
bolic profiling in rat plasma. Agilent 1100 HPLC (Agilent
Technologies, Palo Alto, CA, USA), a radiometric detector
FLO-ONE/625TR (PerkinElmer), and an LCQ Deca XP
Plus (Thermo Fisher Scientific) were used for LC coupled
with an MS system (LC-RAD/MS) to confirm whether
each radioactivity peak was derived from several metabo-
lites in the metabolic profiling in rat urine, bile, and
plasma. Agilent 1100 and 3133 (Shiseido, Tokyo, Japan)
HPLC coupled with TSQ Quantum Discovery Max
(Thermo Fisher Scientific) were used for selected reaction
monitoring analysis (SRM) to identify the in vivo
metabolites with their authentic standards in mouse, rat,


































Fig. 1 Chemical structures of YM758 monophosphate with tentative
numbering. (Asterisk 14C labeled position), YM-385459 (R3), YM-




This study was conducted in male B6C3F1 mice and Fis-
cher 344 (F344) rats (both 9 weeks old) supplied by
Charles River Japan (Kanagawa, Japan), 18-week-old
female New Zealand white (NZW) rabbits supplied by
Kitayama Labes (Nagano, Japan), 11-month-old male
Beagle dogs supplied by the Institute for Animal Repro-
duction (Ibaraki, Japan), and C3-year-old male cynomol-
gus monkeys supplied by KEARI Co., Ltd. (Osaka, Japan).
Mice, rats, and rabbits were used after acclimatization for
at least 1 week, and dogs and monkeys were used after
acclimatization for 16 and 22 days, respectively. The body
weights of mice, rats, rabbits, dogs, and monkeys were
20.2–24.8 g, 168.2–186.9 g, 2.85–3.17 kg, 9.10–10.60 kg,
and 3.24–3.36 kg, respectively. The animal experiments
were approved by an ethics committee and conducted in
accordance with the institutional guidelines of the test
facilities. The doses of YM758 were set according to the
results of toxicity studies to avoid toxicity.
2.4 Metabolic Profiling in Rat Urine, Bile,
and Plasma
Male F344 rat urine and bile samples collected for 0–6 and
6–24 h and plasma samples collected at 0.5 and 1 h
(plasma and bile, n = 3 each; urine, n = 4) after a single
oral administration of 14C-labeled YM758 (14C-YM758) at
a dose of 1 mg free base/kg were obtained in a previous
study [7]. The urine and bile samples were pooled
according to the time interval in which they were collected,
and the pooled samples were used for analysis. The plasma
samples were pooled according to the time point at which
they were collected, and the pooled plasma samples were
then deproteinized using acetonitrile and centrifuged. The
supernatant was concentrated under a stream of nitrogen
gas, and the remaining aqueous solution was centrifuged.
The supernatant was then used for analysis.
The analytical samples and isolated metabolites were
subjected to LC-RAD/MS, and the retention times (RTs) of
radioactivity peaks in the biological samples and the
ultraviolet (UV) peaks of the isolated metabolites were
compared. MS analysis confirmed whether a radioactivity
peak contained several metabolites.
2.5 Identification of Metabolites of YM758
in Mouse, Rat, Rabbit, Dog, and Monkey
Plasma
To identify the metabolites detected in humans [8], YM758
monophosphate was given to mice, rats, rabbits, and dogs
at the single oral doses of 250, 250, 10, and 10 mg/kg,
respectively, and was given to monkeys at a single intra-
venous dose of 3 mg/kg. Mouse, rat, rabbit, and dog blood
samples were obtained at 1, 2, 6, and 24 h after adminis-
tration using a heparinized syringe, and monkey blood
samples were obtained at 0.5, 1, 2, and 4 h after adminis-
tration using a heparinized syringe. The blood samples
were centrifuged and plasma samples were obtained. To
confirm the presence of unchanged YM758 and its
metabolites, 1.5-ml portions of plasma samples in each
animal were diluted with 1.5 ml of 1 % acetic acid and
applied to a solid-phase extraction cartridge, Oasis HLB
(Waters). The extracts were analyzed using a LC-MS, and
the metabolites were detected by SRM. The metabolites,
R3, R4, R8, and R16, were identified using the synthetic
authentic standards, YM-385459, YM-252124, YM-
385461, and AS2036329-00.
2.6 Isolation and Structure Elucidation
of Metabolites
YM758 monophosphate was suspended in 0.5 % methyl-
cellulose to prepare 40 mg free base/ml of dosing sus-
pension. This suspension was given to rats at an oral dose
of 200 mg free base/kg, and urine samples were collected
for 24 h post-dose. The dosing suspension was also given
to bile duct-cannulated rats at the same dosage, and bile
samples were collected for 24 h post-dose.
An aliquot volume (about 202 ml) of the pooled rat
urine was applied to an Oasis HLB (35 cc/6 g) cartridge.
The cartridge was then washed with 50 ml of water and
eluted with 60 ml of acetonitrile. The eluted fraction was
then subjected to preparative HPLC, and six metabolites,
R1 (3.23 mg), R2 (0.51 mg), R3 (6.77 mg), R4
(31.44 mg), R8 (1.04 mg), and R9 (1.04 mg), were
isolated.
An aliquot volume (about 125 ml) of the pooled rat bile
was lyophilized, the residue was subjected to preparative
HPLC, and 11 metabolites, R10 (5.85 mg), R11 (0.99 mg),
R12 (0.57 mg), R13 (2.67 mg), R14 (1.00 mg), R16
(43.37 mg), R17 (4.87 mg), R18 (0.05 mg), R19
(1.49 mg), R20 (4.14 mg), and R21 (0.51 mg), were
isolated.
The isolated metabolites and YM758 monophosphate
were subjected to MS and NMR analysis. Tetramethylsi-
lane was used as the reference for NMR chemical shifts.
NMR measurement of R19 was conducted using
dimethylsulfoxide-d6, and methanol-d4 was used for the
other metabolites and YM758. To elucidate the structure of
R9, the synthetic sample, YM-234903, which is estimated
to be the same structure, was used and their NMR spectra
compared. Two-dimensional NMR analysis was performed
to obtain further information such as elucidation of the
conjugating position. A high-resolution MS, Q-TOF
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Ultima, was used to determine the molecular formula of R3
and R8.
2.7 Analytical HPLC Conditions
Common HPLC conditions were used for LC-RAD/MS
and LC-RAD. HPLC analysis was performed using an
Inertsil ODS-3 column (5 lm, 250 mm 9 4.6 mm i.d., GL
Sciences, Tokyo, Japan) operating at 40 C. A flow rate of
1 ml/min was used with a gradient elution using solvent A
(10 mmol/l ammonium acetate/acetonitrile = 19/1) and B
(10 mmol/l ammonium acetate/acetonitrile = 1/19). The
proportion of solvent B was increased linearly from 0 to
20 % over 30 min, and then increased linearly up to 40 %
between 30 and 45 min, and then increased linearly up to
100 % between 45 and 60 min, and held at 100 % between
60 and 65 min. Except for the analytes from rat plasma
samples, the radioactivity of 14C was monitored using an
online radiometric detector. Radiometric analysis for rat
plasma samples required HPLC fractionation, and the
radioactivity of 14C was detected using a liquid scintillation
counter because of the low level of radioactivity. The
fractionation was performed using a fraction collector to
separate into 120 eluate fractions (30-s interval).
3 Results
3.1 Metabolic Profiling in Rat Plasma, Urine,
and Bile
The radiochromatograms of the urine samples collected for
0–6 and 6–24 h after oral administration showed the
radioactivity peaks derived from at least seven different
metabolites, R1–R4, R9–R10, R19, and YM758 (Fig. 2).
MS analysis confirmed that each peak was derived from
one metabolite. From the radiochromatogram of urine
obtained at 0–6 h (Fig. 2a), the major metabolite was
estimated to be R10, and it accounted for 23.0 % (calcu-
lated from the peak area) of the urinary radioactivity. The
unchanged drug was also detected, representing 15.6 % of
the urinary radioactivity. Relatively large peaks, repre-
senting R9, R4, R19, and R3, accounted for 7.2, 17.6, 14.4,
and 13.1 % of the urinary radioactivity, respectively. From
the radiochromatogram of the urine sample obtained at
6–24 h after administration (Fig. 2b), the major metabolite
was estimated to be R4; it accounted for 25.8 % of the
urinary radioactivity. The unchanged drug was also
detected, representing 9.8 % of the urinary radioactivity.
Relatively large peaks, representing R10, R9, and R3,
accounted for 9.7, 15.6, and 14.6 % of the urinary
radioactivity, respectively.
At least four different radioactivity peaks were observed
on the radiochromatograms of the bile sample collected for
0–6 and 6–24 h after oral administration (Fig. 3), but the
radioactivity peaks were presumed to contain several
metabolites (RT 30.9 min, R14 and R16; RT 33.5 min,
R17–R19; RT 44.4 min, R1 and R2), except for the peak
derived from R10. In the radiochromatogram of rat bile
obtained at 0–6 h (Fig. 3a), the major metabolite was
estimated to be R10, and it accounted for 37.0 % of the
biliary radioactivity. A peak representing the unchanged
drug was not detected. The mixtures of R14 and R16, R17–
R19, and R1 and R2 accounted for 20.4, 25.4, and 17.2 %
of the biliary radioactivity, respectively. The main
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Fig. 4 Radiochromatograms of rat plasma samples collected at 0.5 h (a) and 1 h (b) after oral administration of 14C-YM758 at 1 mg/kg
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administration was also estimated to be R10 (Fig. 3b), and
it accounted for 33.9 % of the biliary radioactivity. The
mixtures of R14 and R16, R17–R19, and R1 and R2
accounted for 24.4, 22.5, and 12.5 % of biliary radioac-
tivity, respectively.
The excretion rates and percentage of dose of the
metabolites were calculated from the results described
above and are shown in Table 3.
The radiochromatograms of plasma obtained at 0.5 and
1 h after oral administration showed several peaks derived
from the metabolites and the unchanged drug (Fig. 4).
These radiochromatograms of plasma at 0.5 and 1 h were
very similar to those of urine collected during the 0–6 h
period after dosing. Radioactivity peaks at RTs of 15.5,
19.5, 30.5, 33.5, 35.5, 44.0, and 50.0 min were estimated to
be R10, R9, R4, R19, R3, the mixture of R1 and R2, and
the unchanged drug, respectively. The major metabolites in
rat plasma were estimated to be both R4 and R10.
3.2 Identification of Metabolites of YM758
in Mouse, Rat, Rabbit, Dog, and Monkey
Plasma
On the SRM chromatograms, four metabolites, R3 (YM-
385459), R4 (YM-252124), R8 (YM-385461), and R16
(AS2036329), were detected in the plasma samples col-
lected 2 h post-dose from mice, rats, rabbits, and dogs, and
0.5 h post-dose from monkeys (Fig. 5). Therefore, those
metabolites were identified as circulating metabolites of
YM758. The detected peaks in the plasma samples of other
time points were not essentially different (data not shown).
3.3 Structure Elucidation of Metabolites of YM758
in Rats
The structures of YM758 and its metabolites were unam-
biguously assigned by the acquisition and rationalization of
their 1H and 13C-NMR signals (Table 1). Although we
were not able to assign NMR chemical shifts of R9 to the
estimated structure, its structure was elucidated according
to the comparison of NMR spectra with the authentic
sample (YM-234903). The molecular weight, mass shifts
from the unchanged drug, and proposed chemical struc-
tures of the metabolites are listed in Table 2.
Both R1 and R2 were estimated to be 21-hydroxylated
metabolites of YM758. Although they were isolated sepa-
rately in the course of the metabolite isolation, their RTs
were almost the same. Given the result of the NMR anal-
ysis, they were considered to represent diastereomers at the
position of the hydroxyl group. The current study was
unable to determine the stereochemical structures of R1
and R2. R3 was formed by elimination of the N-ethyl(4-
fluorophenyl)carboxamide moiety and oxidation of the
piperidine ring. R4 was estimated to be the oxidative
elimination product of the N-ethyl(4-fluorophenyl)carbox-
amide moiety of YM758. R8 was 2-[(4-fluorophenyl)-car-
bonylamino] acetic acid. R9 was estimated to be (3R)-1-{2-
[(4-fluorobenzoyl)amino]ethyl}piperidine-3-carboxylic
acid. Both R10 and R11 were O-b-glucuronides of
demethylated R4. Both R16 and R17 were O-b-glu-
curonides of demethylated YM758. R18 was a sulfate of
R1 or R2. R19 was a ring-cleavage metabolite at positions
18–19 of YM758. R20 was a sulfate conjugate of
31-demethylated YM758. R21 was a sulfate conjugate of
29-demethylated YM758. Although R12, R13, and R14
were estimated to be glutathione conjugates and their
sequential metabolites according to the molecular weights,
we were unable to further elucidate the detail of the
structures because of the limited amounts of the samples
obtained.
4 Discussion
In this study, we conducted in vivo quantitative metabolic
profiling of YM758 in rats using urine, bile, and plasma
samples collected after oral administration of 14C-YM758
1 mg/kg. The main metabolite generated was R10
(22.14 % of dose, Table 3). In addition, other metabolite
peaks, R1–R4, R9, R14, R16–R19, were detected in the
urine and bile samples. These metabolites were generated
via various metabolic pathways. Therefore, the metabolism
of YM758 in rats is considered to be diverse. The meta-
bolic profile in plasma at 0.5 and 1 h was similar to that in
the urine, and the main circulating metabolites in rats were
thought to be R4 and R10. Although R11 was isolated from
the rat bile collected after a large dosage of YM758, and
the structure was elucidated using NMR and MS, it was not
detected in the radiochromatograms of rat plasma, urine,
and bile samples.
The presence of the metabolites R3, R4, R8, and R16,
which have already been found in human plasma [8], were
also found in the plasma of mice, rats, rabbits, dogs, and
monkeys after a single administration of YM758. These
results suggest that there are no human-specific circulating
metabolites. Consequently, we intend to conduct pharma-
cokinetic studies to confirm the exposure to the metabolites
in the experimental animals.
After oral administration of a large quantity of YM758
to rats, bile and urine samples were collected for up to
24 h. Metabolites R1–R4, R8, and R9 were isolated from
the urine samples, and R10–R14 and R16–R21 were iso-
lated from the bile samples via chromatographic separa-
tion. The chemical structures were elucidated with MS and
NMR analyses. The postulated metabolic pathways are
shown in Fig. 6. The main metabolic pathways of YM758
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Fig. 5 Selected reaction
monitoring chromatograms of
R3 (a), R4 (b), R8 (c), and R16
(d) in plasma samples collected
from mice, rats, rabbits, dogs,
and monkeys after a single dose
of YM758, and authentic
samples of those metabolites
Metabolite Profile of YM758 211
Table 1 1H and 13C-NMR assignment for YM758 monophosphate and its metabolites isolated from rat urine and bile samples
Position YM758 R1 R2 R3 R4 R8
dH dC dH dC dH dC dH dC dH dC dH dC
Basic structure of unchanged drug
1 – 166.5 – ND – ND – – – – – 167.0
2, 6 7.20 116.5 7.20 116.4 7.21 116.5 – – – – 7.19 116.0
3, 5 7.97 131.3 7.90 131.1 7.91 131.0 – – – – 7.91 131.0
4 – 131.4 – ND – ND – – – – – 132.0
7 – 169.8 – ND – ND – – – – – 169.0
9 3.80 36.0 3.65 36.8 3.60 37.0 – – – – 4.05 43.0
3.70
10 3.29 58.1 3.04 58.3 2.90 ND – – – – – ND
12 3.27 54.2 4.65 47.8 4.57 48.0 3.36 44.5 3.23 47.0 – –
3.31 4.75 48.1 4.64 3.46
13 3.52 37.5 2.90 ND ND ND 3.27 37.0 3.27 36.5 – –
14 1.72 26.3 1.72 27.0 1.77 ND 1.94 25.0 1.72 26.5 – –
2.01 1.93 1.97 1.98 1.92
2.03
15 1.93 22.7 1.86 23.5 1.85 ND 2.43 31.0 1.83 22.0 – –
2.06 1.91
16 3.16 55.5 3.17 54.7 3.10 55.0 – 174.5 3.08 45.0 – –
3.42 55.6 3.31 3.18 56.0 3.18
17 – 173.2 – ND – ND – 173.5 – 174.0 – –
18 4.52 45.2 4.17 45.0 4.29 45.0 4.59 45.5 4.56 45.0 – –
4.62 5.11 4.96 4.63 4.65
4.67 48.2 4.71 48.2 4.64 48.0
4.72
20 3.78 41.7 3.61 51.5 3.66 51.5 3.78 42.0 3.74 44.5 – –
3.80 4.06 3.95 3.80 44.5 3.77 42.0
3.71 44.8
3.79
21 2.75 28.7 4.70 67.0 4.70 67.0 2.77 29.0 2.76 29.0 – –
2.87 30.1 2.87 30.0 2.86 30.0
22 – 127.6 – ND – ND – 127.0 – 128.0 – –
128.1 128.0
23 6.73 113.1 6.96 113.5 6.98 113.0 6.75 113.0 6.74 113.0
6.74 113.2 7.01 112.7 7.01 112.5 – –
24 – 149.4 – ND – ND – 150.0 – 150.0 – –
149.5
25 – 149.5 – ND – ND – 150.0 – 150.0 – –
149.7
26 6.71 111.1 6.74 110.2 6.75 110.1 6.75 111.0 6.73 111.0 – –
6.83 6.80 110.1 6.80 110.0 6.79
27 – 126.0 – ND – ND – 126.0 – 126.0 – –
126.1 127.0
29 3.79 56.6 3.82 56.6 3.81 56.5 3.80 56.5 3.79 56.5 – –
31 3.79 56.6 3.83 56.6 3.82 56.5 3.80 56.5 3.79 56.5 – –
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Table 1 continued
Position R10 R11 R16 R17 R18 R19 R20 R21
dH dH dH dC dH dC dH dH dC dH dH
Basic structure of unchanged drug
1 – – – ND – ND – – 164.0 – –
2, 6 – – 7.19 116.0 7.15 116.0 7.23 7.27 115.7 7.22 7.22
3, 5 – – 7.89 131.0 7.89 131.0 7.90 7.95 130.5 7.94 7.91
4 – – – ND – ND – – 131.9 – –
7 – – – ND – ND – – 165.0 – –
9 – – 3.61
3.68
37.0 3.74 36.0 3.67 3.34 37.7 ND ND
10 – – 2.91 58.0 3.30 ND 3.0–3.4 2.40 57.8 ND ND
2.45
12 3.11 3.10 2.58 57.0 3.36 58.0 3.0–3.7 2.00 56.6 ND ND
3.19 3.24 3.15 2.76
13 3.24 3.15 3.15 39.0 3.10 ND ND 2.20 43.0 ND ND
14 1.72 1.75 1.61 ND 1.72 26.0 1.85 or 1.94 1.30 27.6 ND ND
1.97 1.92 1.81 1.93 1.59
15 1.82 1.86 1.81 ND 1.93 23.0 1.37 24.9 ND ND
1.88 1.55
16 3.02 3.04 2.58 57.0 3.36 58.0 3.0–3.7 1.93 54.0 ND ND
3.11 3.10 3.15 2.69
3.25 3.16
17 – – – ND – ND – – 181.5 – –
18 4.51 4.55 4.59 45.5 4.47 45.0 4.72 – 173.8 4.49 4.60
4.57 4.68 48.0 4.59 48.0 4.67
20 3.63 3.65 3.72 42.0 3.55 42.0 3.63 3.24 42.1 3.70 ND
3.71 3.78 3.73 45.0 3.82 4.02 3.74
3.80
21 2.78 2.76 2.73 29.0 2.78 28.0 ND 3.00 32.8 2.73 ND
2.85 2.81 2.83 2.81
22 – – – ND – ND – – ND – –
23 6.79 7.00 7.01 118.0 6.74 114.0 7.03 6.71 114.1 7.21 6.81
6.80 7.02 7.03 6.78 7.09
24 – – – ND – ND – – 150.0 – –
25 – – – ND – ND – – 146.8 – –
26 7.02 6.78 6.76 112.0 6.94 115.0 7.29 7.27 114.1 6.74 7.28
7.04 6.81 6.83 7.05 7.32
27 – – – ND – ND – – 130.0 – –
29 – 3.83 3.82 57.0 – – – 3.71 56.0 3.78 –
31 3.82 – – – 3.80 57.0 3.84 3.75 56.0 – 3.80
3.83
Glucuronic acid
10 4.93 4.92 4.84 103.0 4.99 103.0 – – – – –
20, 30, 40, 50 3.51 3.50 74.0 3.55 75.0 – – – – –
3.54 3.52 3.50 78.0 3.55 75.0
3.80 3.73 3.50 77.0 3.55 77.0
3.70 3.74 77.0
60 – – – ND – ND – – – – –
‘–’ indicates not applicable, ND not detected
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Table 2 Nominal mass, mass








(unit) Estimated chemical structure





































































































Glu glucuronic acid, NA not applicable
Table 3 Excretion rate of
YM758 and its metabolites in
rat urine and bile










Mixture of R14 and R16 NC 11.41
Mixture of R17, R18, and R19 NA 13.67
Sole R19 1.24 NA
YM758 1.52 NC
NA not applicable, NC not calculated because of the trace amount or undetectable metabolite
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in rats are thought to be (1) hydroxylation (R1, R2, and
R18); (2) oxidation followed by hydration (R3, R4, R8, and
R19); (3) amide hydrolysis (R9); (4) O-demethylation
followed by sulfate or glucuronide conjugation (R10, R11,
R16–R18, R20, and R21).
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Fig. 6 Postulated metabolic pathways of YM758
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